Clinical trials: Unspecified Adult Solid Tumor, Protocol Specific, completed
Lymphoma, Lymphoproliferative Disorder
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
RATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of KX2-391 in treating patients with advanced…
- Conditions
- Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00646139
- Testing
- Src kinase inhibitor KX2-391, immunoenzyme technique, pharmacological study
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in…
- Trial name
- NCT00020657
- Testing
- dolasetron mesylate, granisetron hydrochloride, ondansetron
- Where
- 15 sites in United States
- Sponsor
- Gary Morrow
Unspecified Adult Solid Tumor, Protocol Specific
FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents
This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with metastatic solid tumors receiving treatment that…
- Trial name
- NCT02055586
- Testing
- fluorine F 18 fluorothymidine, positron emission tomography, magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Chemotherapeutic Agent Toxicity, Neutropenia
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
RATIONALE: Colony-stimulating factors, such as G-CSF, may increase the number of white blood cells found in bone marrow or peripheral blood and may prevent persistent neutropenia in patients receiving chemotherapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00770172
- Testing
- filgrastim
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Centre Francois Baclesse
Unspecified Adult Solid Tumor, Protocol Specific
MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004886
- Testing
- docetaxel, dofequidar fumarate
- Where
- 3 sites in France, Germany
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Spinal Cord Compression, Unspecified Adult Solid Tumor, Protocol Specific
Radiation Therapy in Treating Patients With Metastatic Spinal Cord Compression
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating metastatic spinal cord compression.
- Trial name
- NCT00727584
- Testing
- radiation therapy
- Where
- 4 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Cancer Research UK
Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
MEN-10755 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MEN-10755 in treating patients who have solid tumors.
- Trial name
- NCT00003982
- Testing
- sabarubicin
- Where
- 27 sites in Austria, Belgium and 7 more
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adult, Solid Tumor
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
RATIONALE: LY317615 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor.
- Trial name
- NCT00052273
- Testing
- capecitabine, enzastaurin hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00027937
- Testing
- aldesleukin, filgrastim, sargramostim
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Geldanamycin Analogue in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of a geldanamycin analogue in treating…
- Trial name
- NCT00003969
- Testing
- tanespimycin
- Where
- United Kingdom
- Sponsor
- Cancer Research UK
Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Trial name
- NCT00021164
- Testing
- aldesleukin, incomplete Freund's adjuvant, telomerase: 540-548 peptide vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have an advanced malignancy (cancer) or stage IV melanoma.
- Trial name
- NCT00073892
- Testing
- PI-88
- Where
- 5 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Cellxpert Biotechnology Corp.
Unspecified Adult Solid Tumor, Protocol Specific
Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors
RATIONALE: Aurora B/C kinase inhibitor GSK1070916A (GSK1070916A) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01118611
- Testing
- Aurora B/C kinase inhibitor GSK1070916A, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Cancer Research UK
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00388089
- Testing
- bortezomib, topotecan hydrochloride, flow cytometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Davis
Breast Cancer, Cancer Survivor
Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer
RATIONALE: Magnesium oxide may help relieve hot flashes in women with cancer. PURPOSE: This phase II trial is studying how well magnesium oxide works in treating hot flashes in menopausal women with cancer.
- Conditions
- Breast Cancer, Cancer Survivor, Hot Flashes, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01008904
- Testing
- magnesium oxide, questionnaire administration, quality-of-life assessment
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating patients with advanced…
- Trial name
- NCT00390117
- Testing
- CDKI AT7519, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Unspecified Adult Solid Tumor, Protocol Specific
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
RATIONALE: 2-Methoxyestradiol may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of 2-methoxyestradiol in treating patients who have advanced solid tumors.
- Trial name
- NCT00030095
- Testing
- 2-methoxyestradiol
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00276575
- Testing
- bevacizumab, erlotinib hydrochloride, everolimus
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Herbert Hurwitz, MD
Leukemia, Lymphoma
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00019656
- Testing
- perifosine
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cachexia, Fatigue
Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss
RATIONALE: Megestrol helps improve appetite. Exercise may decrease cancer-related fatigue, improve strength, and build up lost muscle tissue. Exercise plus megestrol may be effective treatment for cancer-related weight loss.
- Conditions
- Cachexia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004912
- Testing
- megestrol acetate, physical therapy
- Where
- 6 sites in United States
- Sponsor
- Northwestern University